STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uteri

Trial Details

NCT ID
NCT06975293
Phase
PHASE1 / PHASE2
Sponsor
STORM Therapeutics LTD
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • STC-15 in combination with toripalimab
  • STC-15 monotherapy
Locations (sample)
  • Lake Success, New York, United States|40.77066,-73.71763
  • Houston, Texas, United States|29.76328,-95.36327
  • Irving, Texas, United States|32.81402,-96.94889
  • San Antonio, Texas, United States|29.42412,-98.49363
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Estimated life expectancy ≥ 3 months.
  • ECOG performance status 0 or 1.
  • Measurable disease according to RECIST v1.1 as assessed by the local site investigator/radiology.
  • Documented radiologic assessment of progression on the prior therapy before study entry.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →